In 1995, the National Institute of Neurological Disorders and Stroke (NINDS) trial marked a new era in stroke therapy when it demonstrated an improved clinical outcome at 90 days in AIS patients who received tPA intravenously, with a number needed to treat (NNT) of 7.7 [13]. This evidence concerns the gene PLAT and Stroke.